It will be "an abbreviated pathway that will depend on existing data" on the already-existing, more-expensive drug, said Rachel Sherman, FDA associate director for medical policy.
After analyzing the data, the Wake Forest Baptist researchers identified the cell signaling pathway by which epinephrine, a hormone also known as adrenaline, sets off the cellular chain reaction that controls cell death.